Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $18.0 million.

  • Heron Therapeutics' Change in Acquisitions & Divestments fell 4023.83% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.3 million, marking a year-over-year decrease of 2597.42%. This contributed to the annual value of $123.5 million for FY2024, which is 1520.27% up from last year.
  • Heron Therapeutics' Change in Acquisitions & Divestments amounted to $18.0 million in Q3 2025, which was down 4023.83% from $16.7 million recorded in Q2 2025.
  • Heron Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $58.0 million during Q2 2021, with a 5-year trough of $13.5 million in Q3 2023.
  • In the last 5 years, Heron Therapeutics' Change in Acquisitions & Divestments had a median value of $29.9 million in 2024 and averaged $31.6 million.
  • In the last 5 years, Heron Therapeutics' Change in Acquisitions & Divestments crashed by 8617.28% in 2021 and then soared by 12256.3% in 2024.
  • Over the past 5 years, Heron Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $14.0 million in 2021, then surged by 50.0% to $21.0 million in 2022, then dropped by 29.76% to $14.8 million in 2023, then soared by 65.23% to $24.4 million in 2024, then decreased by 26.32% to $18.0 million in 2025.
  • Its last three reported values are $18.0 million in Q3 2025, $16.7 million for Q2 2025, and $25.2 million during Q1 2025.